Moderna is pioneering messenger RNA therapeutics
Moderna Therapeutics is developing messenger RNA therapeutics, an entirely new drug modality designed to produce human proteins or antibodies within a patient’s cells. This revolutionary platform holds the potential to treat diseases that cannot be addressed using existing technology and may improve upon existing drug modalities for a wide range of conditions. If successful, Moderna Therapeutics’ messenger RNA technology will usher in the first entirely new way of making therapeutic proteins since the development of recombinant technology more than 30 years ago, representing an important advance for both patients and industry.
Moderna Therapeutics’ approach can be applied to meet patient needs across a broad range of diseases. We can generate and test new drug candidates of messenger RNA therapeutics in animals in a matter of weeks, dramatically accelerating the speed of drug development, as well as reducing the cost and risk traditionally associated with discovering and delivering new medicines to patients. This speed, and the flexibility of our enabling technology to address any number of diseases, is giving rise to a robust portfolio of therapeutic candidates.
The company will initially focus in key areas where high unmet needs demand safe, efficacious, and innovative therapies: oncology supportive care, inherited genetic disorders, hemophilia, and diabetes. Moderna Therapeutics has a strategic option agreement with AstraZeneca in other disease areas to ensure this important innovation reaches patients as quickly as possible.
Moderna Therapeutics has completed preclinical proof-of-concept studies showing that messenger RNA therapeutics can successfully induce in vivo production of dozens of proteins through intra-muscular, subcutaneous, and intravenous administration, and has demonstrated safety and efficacy in multiple preclinical models, including non-human primates. The ability of our platform to induce protein production and achieve a therapeutic effect in a mouse model of myocardial infarction is described in a peer-reviewed publication that appeared in Nature Biotechnology.
Moderna Therapeutics is a privately held company based in Cambridge, Massachusetts, and is well-funded by Flagship Ventures and private investors.